UNASSIGNED: A retrospective analysis of patients undergoing ALPPS from September 2022 to December 2023 was performed.
UNASSIGNED: A total of 25 patients underwent the ALPPS procedure: 21 procedures for hepatocellular carcinoma (HCC), 3 combined hepatocellular-cholangiocarcinoma (cHCC-CCA), and 1 for small cell neuroendocrine carcinoma (SNEC). The mean postoperative stay was 29.6 ± 9.3 days (range 16-58 days). After stage 1, we counted 8 complications, all of grade II; after stage 2, the number of complications was decreased to 3:2 were of grade I and 1 were of grade IIIB. 3 (12%) patients failed to proceed to ALPPS stage 2. After a median follow-up of 9 months (range 2-25), disease recurrence has been recorded in 3 patients (12%), while 1 patient (4%) died, affected by HCC. The entire group\'s 2-year overall survival (OS) and disease-free survival (DFS) were 83.3% and 82.5%, respectively.
UNASSIGNED: The ALPPS procedure is an approach for large liver tumors with small future liver remnant with acceptable OS and DFS in a low-income and middle-income country.
■对2022年9月至2023年12月接受ALPPS的患者进行了回顾性分析。
■共有25例患者接受了ALPPS手术:21例肝细胞癌(HCC)手术,3联合肝细胞胆管癌(cHCC-CCA),1为小细胞神经内分泌癌(SNEC)。术后平均住院时间为29.6±9.3天(范围16-58天)。在第1阶段之后,我们计算了8个并发症,全部为II级;在第2阶段后,并发症的数量减少到3:2为I级,1为IIIB级。3例(12%)患者未能进入ALPPS2期。经过9个月的中位随访(范围2-25),已记录3例患者(12%)的疾病复发,1名患者(4%)死亡,受HCC影响。全组2年总生存率(OS)和无病生存率(DFS)分别为83.3%和82.5%,分别。
■ALPPS程序是一种在低收入和中等收入国家中具有可接受的OS和DFS的未来肝脏残留小的大型肝脏肿瘤的方法。